Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 625

Sort by

Sort Order Select

Journal Articles

POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Pankit Vachhani, Raajit Rampal, Terrence Bradley, Claire Harrison, Tania Jain, Andrew T. Kuykendall, Francesca Palandri, John O. Mascarenhas, Haifa Kathrin Al-Ali, Francesco Passamonti, Anna Nekhymchuk, Hilarie Foss, Wayne Rothbaum, Srdan Verstovsek, Florian Heidel

Blood (2024) 144 (Supplement 1): 1808.2.

https://doi.org/10.1182/blood-2024-200966

Published: 2024

Journal Articles

Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed / Refractory Myelofibrosis

John O. Mascarenhas, Viola Maria Popov, Sanjay Mohan, Zübeyde Nur Özkurt, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Andrew Perkins, Zhuying Huang, Hope Qamoos, Jesse McGreivy, Wayne Rothbaum, Srdan Verstovsek, Maciej Kaźmierczak

Blood (2024) 144 (Supplement 1): 1000.

https://doi.org/10.1182/blood-2024-201642

Published: 2024

Journal Articles

Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis

John O. Mascarenhas, Prithviraj Bose, Hsin-An Hou, Wojciech Homenda, David Ross, Sanjay R Mohan, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Andrew Perkins, Yulia Khalina, Tracy Clevenger, Zhuying Huang, Jesse McGreivy, Wayne Rothbaum, Srdan Verstovsek, Alessandro M. Vannucchi

Blood (2024) 144 (Supplement 1): 483.

https://doi.org/10.1182/blood-2024-205937

Published: 2024

Journal Articles

Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocytopenia and Polycythemia Vera: Final Analysis Focused on the Two Diseases

Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Gautam Borthakur, Srdan Verstovsek, C. Cameron Yin, Keyur P. Patel, Hagop M. Kantarjian

Blood (2024) 144 (Supplement 1): 1807.

https://doi.org/10.1182/blood-2024-211674

Published: 2024

Journal Articles

A Phase (Ph) 2 Study of TL-895, a Highly Selective, Novel Covalent BTK Inhibitor (BTKi), in Patients (pts) with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) BTKi-Naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Blood (2023) 142 (Supplement 1): 4634.

https://doi.org/10.1182/blood-2023-186517

Published: 2023

Journal Articles

Phase I Study of the T-Cell Receptor-like Antibody, Hu8F4 in Patients with Relapsed and Refractory Myeloid Malignancies

Blood (2023) 142 (Supplement 1): 1545.

https://doi.org/10.1182/blood-2023-189966

Published: 2023

Journal Articles

Multicenter Retrospective Analysis of Eosinophilic Myeloid Neoplasms

Blood (2023) 142 (Supplement 1): 4576.

https://doi.org/10.1182/blood-2023-187092

Published: 2023

Journal Articles

CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL

Blood (2023) 142 (Supplement 1): 3264.

https://doi.org/10.1182/blood-2023-190712

Published: 2023

Journal Articles

Neoplastic Monocyte-Derived Fibrocytes Induce Bone Marrow Fibrosis in Patients with Primary Myelofibrosis

Ivo Veletic, Taghi Manshouri, Christopher D. Pacheco, C. Cameron Yin, Ying Zhang, Ping Li, Evan N. Cohen, Javier A. Gomez, Jared K. Burks, Srdan Verstovsek, Zeev Estrov

Blood (2023) 142 (Supplement 1): 4516.

https://doi.org/10.1182/blood-2023-191024

Published: 2023

Journal Articles

Deep and Durable Cytogenetic and Molecular Responses with Pemigatinib in Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement: The Fight-203 Study

Blood (2023) 142 (Supplement 1): 4551.

https://doi.org/10.1182/blood-2023-180945

Published: 2023

Journal Articles

Long Term Results of Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocythemia and Polycythemia Vera: Median Follow-up of 15 Years

Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Mary Ann Richie, Gautam Borthakur, Zeev E. Estrov, Hagop Kantarjian, Keyur P. Patel, Srdan Verstovsek

Blood (2022) 140 (Supplement 1): 9683–9684.

https://doi.org/10.1182/blood-2022-165538

Published: 2022

Journal Articles

The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study

Blood (2022) 140 (Supplement 1): 9677–9680.

https://doi.org/10.1182/blood-2022-162547

Published: 2022

Journal Articles

Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)

Blood (2022) 140 (Supplement 1): 9670–9672.

https://doi.org/10.1182/blood-2022-162543

Published: 2022

Journal Articles

Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study

Claire Harrison, Marina Kremyanskaya, Prithviraj Bose, Vikas Gupta, Raajit K Rampal, Jonathan Lambert, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian, Srdan Verstovsek, Ruben Mesa, Gozde Colak, Sandra Klein, Soumik Dutta, John Mascarenhas

Blood (2022) 140 (Supplement 1): 9659–9662.

https://doi.org/10.1182/blood-2022-157735

Published: 2022

Journal Articles

PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary or Secondary Myelofibrosis and Severe Thrombocytopenia

John Mascarenhas, Aaron T. Gerds, Jean-Jacques Kiladjian, Konstanze Döhner, Sarah Buckley, Jennifer A. Smith, Adam R Craig, Simran Bedi Singh, Srdan Verstovsek, Claire Harrison

Blood (2022) 140 (Supplement 1): 9592–9594.

https://doi.org/10.1182/blood-2022-163456

Published: 2022

Journal Articles

A Phase 1/2 Study of INCB000928 As Monotherapy or Combined with Ruxolitinib (RUX) in Patients (Pts) with Anemia Due to Myelofibrosis (MF)

Sanjay R Mohan, Stephen T Oh, Haris Ali, Anthony M. Hunter, Francesca Palandri, Betty Lamothe, Yi Cui, Francis Seguy, Amanda McBride, Michael Robert Savona, Jean-Jacques Kiladjian, Srdan Verstovsek

Blood (2022) 140 (Supplement 1): 3943–3944.

https://doi.org/10.1182/blood-2022-169210

Published: 2022

Journal Articles

Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial

Vikas Gupta, Abdulraheem Yacoub, Srdan Verstovsek, Ruben Mesa, Claire Harrison, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, H. Joachim Deeg, Salman Fazal, Lynda Foltz, Ryan J. Mattison, Carole B. Miller, Vinod Parameswaran, Patricia Martin-Regueira, Christopher Hernandez, Jia Wang, Moshe Talpaz

Blood (2022) 140 (Supplement 1): 3935–3937.

https://doi.org/10.1182/blood-2022-156669

Published: 2022

Journal Articles

Verify: A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera

Srdan Verstovsek, Andrew Kuykendall, Ronald Hoffman, Steffen Koschmieder, Francesco Passamonti, Frank Valone, Nishit B. Modi, Sarita Khanna, Paula G. O'Connor, Suneel K. Gupta, Jean-Jacques Kiladjian

Blood (2022) 140 (Supplement 1): 3929–3931.

https://doi.org/10.1182/blood-2022-163755

Published: 2022

Journal Articles

Subgroup Analysis of Adverse Events Following Rusfertide Dosing in Revive: A Phase 2 Study of Patients with Polycythemia Vera

Naveen Pemmaraju, Srdan Verstovsek, Marina Kremyanskaya, Frank Valone, Nishit B. Modi, Sarita Khanna, Paula G. O'Connor, Suneel K. Gupta, Ronald Hoffman

Blood (2022) 140 (Supplement 1): 6835–6837.

https://doi.org/10.1182/blood-2022-163742

Published: 2022

Journal Articles

MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

John Mascarenhas, Claire Harrison, Jean-Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro M. Vannucchi, Tymara Berry, Denise Redding, Laurie Sherman, Souria Dougherty, Lixian Peng, Libo Sun, Fei Huang, Ying Wan, Faye Feller, Srdan Verstovsek

Blood (2022) 140 (Supplement 1): 6826–6829.

https://doi.org/10.1182/blood-2022-160364

Published: 2022

NARROW

POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed / Refractory Myelofibrosis

Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis

Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocytopenia and Polycythemia Vera: Final Analysis Focused on the Two Diseases

A Phase (Ph) 2 Study of TL-895, a Highly Selective, Novel Covalent BTK Inhibitor (BTKi), in Patients (pts) with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) BTKi-Naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Phase I Study of the T-Cell Receptor-like Antibody, Hu8F4 in Patients with Relapsed and Refractory Myeloid Malignancies

Multicenter Retrospective Analysis of Eosinophilic Myeloid Neoplasms

CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL

Neoplastic Monocyte-Derived Fibrocytes Induce Bone Marrow Fibrosis in Patients with Primary Myelofibrosis

Deep and Durable Cytogenetic and Molecular Responses with Pemigatinib in Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement: The Fight-203 Study

Long Term Results of Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocythemia and Polycythemia Vera: Median Follow-up of 15 Years

The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study

Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)

Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study

PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary or Secondary Myelofibrosis and Severe Thrombocytopenia

A Phase 1/2 Study of INCB000928 As Monotherapy or Combined with Ruxolitinib (RUX) in Patients (Pts) with Anemia Due to Myelofibrosis (MF)

Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial

Verify: A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera

Subgroup Analysis of Adverse Events Following Rusfertide Dosing in Revive: A Phase 2 Study of Patients with Polycythemia Vera

MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only